Case Studies: Neurologic Consultations in Cancer Patients II
Sunday April 23, 2017 3:30 pm to 5:30 pm
Patrick Wen MD, FAAN
Neurologists are often called upon to weigh in on management issues related to patients with brain tumors or systemic cancer. They must recognize syndromes that predate cancer diagnosis, complications of therapy, and sequelae.
The program will be divided into three sessions using cases to illustrate 1) the current management and new WHO classification of gliomas, 2) the diagnosis and management of metastatic complications of cancer, and 3) recent developments in the diagnosis and management of paraneoplastic neurologic syndromes. These presentations will be followed by a fourth session involving a tumor board format to discuss cases of interest.
This program complements C38: Case Studies: Neurologic Consultations in Cancer Patients I, but covers independent topics.
Participants should be able to understand the current diagnosis, classification, and management of gliomas; the diagnosis and management of the common metastatic complications of cancer; and the diagnosis and management of paraneoplastic syndromes of the nervous system.
Medical Knowledge, Patient Care
Program Speakers - Tentative
3:30 PM - 4:00 PM
Update on WHO Classification and Treatment of Gliomas
Patrick Y. Wen MD, FAAN
4:00 PM - 4:30 PM
Diagnosis and Management of Metastatic Complications of Cancer
David Schiff MD, FAAN
4:30 PM - 5:00 PM
Diagnosis and Management of Paraneoplastic Syndromes
Josep O. Dalmau MD, PhD, FAAN
5:00 PM - 5:30 PM
Tumor Board Case Studies
Amy A. Pruitt MD
Josep O. Dalmau, MD, PhD, FAAN
Dr. Dalmau has received personal compensation in an editorial capacity for Neurology, Neuroimmunology, Neuroinflammation; and UpToDate. Dr. Dalmau has received royalty, license fees, or contractual rights payments from Euroimmune. Dr. Dalmau has received research support from Euroimmun.
Amy A. Pruitt, MD
Dr. Pruitt has nothing to disclose.
David Schiff, MD, FAAN
Dr. Schiff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Data monitoring committees for Orbus and Monteris.
Patrick Y. Wen, MD, FAAN
Dr. Wen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Abbvie, AstraZeneca, Corice Bioscience, Roche, GW pharmaceuticals, Kadmon, Vascular Biogenics, and Ziopharm. Dr. Wen has received personal compensation in an editorial capacity for Neuro-Oncology, UpToDate, and Elsevier.